Furthermore, in a cohort of 24 AML patients, we found that GRP78-CAR T cells effectively eradicated AML blasts in a fraction of AML specimens (25%) with different FAB subtypes, supporting its promising application for AML treatment. This evidence concerns the gene HSPA5 and acute myeloid leukemia.